Single oral dose of azithromycin versus 5 days of oral erythromycin or no antibiotic in treatment of campylobacter enterocolitis in children: A prospective randomized assessor-blind study

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 4, 2010, Pages 404-410

  Vukelic, Dalibor ^a   Trkulja, Vladimir ^b   Salkovic Petrisic, Melita ^b  

^a Croatia   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Azithromycin; Campylobacter enterocolitis; Children; Erythromycin

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CAMPYLOBACTER COLI; CAMPYLOBACTER ENTERITIS; CAMPYLOBACTER JEJUNI; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; UPPER ABDOMINAL PAIN; VOMITING;

ADMINISTRATION, ORAL; AZITHROMYCIN; CAMPYLOBACTER; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENTEROCOLITIS; ERYTHROMYCIN; FEMALE; HUMANS; INFANT; INTENTION TO TREAT ANALYSIS; MALE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD;

CAMPYLOBACTER;

EID: 77950218169     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181a87104     Document Type: Article

References (29)

1. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect 2004;10:868-876
2. Karmali MA, Fleming PC. Campylobacter enteritis. Can Med Assoc J 1979;120:1525-1532
3. Mishu B, Blaser MJ. The role of Campylobacter jejuni infection in the initiation of Guillain-Barré syndrome. Clin Infect Dis 1993;17:104-108
4. Tsang RS. The relationship of Campylobacter jejuni infection and the development of Guillain-Barre syndrome. Curr Opin Infect Dis 2002;15:221-228
5. Butzler JP, Glupczynski Y, Goossens H. Campylobacter and Helicobacter infections. Curr Opin Infect Dis 1992;5:80-87
6. Mishu-Allos B. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001;32:1201-1206
7. Crushell E, Harty S, Sharif F, et al. Enteritic Campylobacter: purging its secrets? Pediatr Res 2004;55:3-12.
8. Anders BJ, Lauer BA, Paisley JW. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982;1:131-133
9. Klein JO. History of macrolide use in pediatrics. Pediatr Inf Dis J 1997;16:427-431
10. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 2006;58:243-255
11. Guay DRP. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-536
12. Hopkins SJ. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994;5:383-389
13. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 (Suppl A):73-82.
14. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-131
15. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high dose clarithromycin among elderly patients. Diagn Microb Infect Dis 1993;16:215-221
16. Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21: 536-541
17. Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin- based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007;44:338-346
18. Skirrow MB, Blaser MJ. Clinical aspects of Campylobacter infection. In: Nachamkin I, Blaser MJ (eds). Campylobacter. Washington, DC: ASM Press; 2000. pp. 69-88.
19. Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofloxacin vs. intramuscular ceftriaxon as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 2000;15:1060-1067
20. Tolcin R, LaSalvia MM, Kirkley BA, et al. Evaluation of the Alexon- Trend ProSpecT Campylobacter microplate assay. J Clin Microbiol 2000;38:3853-3855
21. Hindiyeh M, Jense S, Hohmann S, et al. Rapid detection of Campylobacter jejuni in stool specimens by an enzyme immunoassay and surveillance for Campylobacter upsaliensis in the Greater Salt Lake City area. J Clin Microbiol 2000;38:3076-3079
22. Dediste A, Vanderberg O, Vlaes L, et al. Evaluation of ProSpect T microplate assay for detection of Campylobacter: a routine laboratory perspective. Clin Microbiol Infect 2003;9:1085-1090
23. Endtz HP, Ang CW, van den Braak N, et al. Evaluation of a new commercial immunoassay for rapid detection of Campylobacter jejuni in stool samples. Eur J Clin Microbiol Infect Dis 2000;19:794-797
24. McNutt LA, Wu Ch, Xue X, et al. Estimating relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940-943
25. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706
26. Ternhag A, Asikainen T, Giesecke J, et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007;44:696-700.
27. Pai CH, Gillis F, Tuomanen E, et al. Erythromycin in treatment of Campylobacter enteritis in children. Am J Dis Child 1983;137:286-288
28. Robins-Browne RM, Mackenjee MK, Bodasing MN, et al. Treatment of Campylobacter-associated enteritis with erythromycin. Am J Dis Child 1983;137:282-285
29. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986;109:355-360